Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antigens, Surface
  • Glutamate Carboxypeptidase II
  • Prostatic Neoplasms

abstract

  • The recommended dose for (90)Y-J591 is 17.5 mCi/m(2). Acceptable toxicity, excellent targeting of known sites of PC metastases, and biologic activity in patients with androgen-independent PC warrant further investigation of (90)Y-J591 in the treatment of patients with PC.

publication date

  • December 2004

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2004.09.154

PubMed ID

  • 15173215

Additional Document Info

start page

  • 2522

end page

  • 31

volume

  • 22

number

  • 13